Literature DB >> 12361906

SN-38 induces cell cycle arrest and apoptosis in human testicular cancer.

Munehisa Ueno1, Shoichi Nonaka, Ryuta Yamazaki, Nobuhiro Deguchi, Masaru Murai.   

Abstract

OBJECTIVE: CPT-11 is one of the most widely used camptothecin analogues and is converted to form the active metabolite SN-38. Clinical trials are ongoing to better characterize its spectra of clinical activity, to determine the optimal schedules of administration, and to define the usage in combination with other chemotherapeutic compounds.
MATERIALS AND METHODS: KU-MT, an AFP-producing testicular carcinoma cell line, was exposed to SN-38, etoposide, or cisplatin for 24 h, and the resulting cytotoxicity was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazonium bromide (MTT) assay. This paper describes the effects of SN-38 on the cell proliferation and cell cycle of testicular tumor cells in culture.
RESULTS: SN-38 was shown to inhibit KU-MT cell growth more potently than either etoposide or cisplatin. A marked decrease in the percentage of S phase cells was accompanied by the enhancement of cyclin E levels. In concentrations of >30 nmol/l, SN-38 arrested the cell cycle in G2 and induced cell death via apoptosis. The apoptosis was promoted by Bax and p53 protein, which were both shown to be present by flow cytometric and Western blot analyses.
CONCLUSION: These results suggest that CPT-11, a pro-drug of SN-38, may be clinically useful for the treatment of testicular cancer, and that the mechanism of this agent's cytotoxicity consists of cell cycle arrest and concomitant apoptosis. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12361906     DOI: 10.1016/s0302-2838(02)00321-4

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  9 in total

1.  Carboxyl-terminated PAMAM-SN38 conjugates: synthesis, characterization, and in vitro evaluation.

Authors:  Nirmalkumar Vijayalakshmi; Abhijit Ray; Alexander Malugin; Hamidreza Ghandehari
Journal:  Bioconjug Chem       Date:  2010-10-20       Impact factor: 4.774

2.  Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.

Authors:  S T Workenhe; T Ketela; J Moffat; B P Cuddington; K L Mossman
Journal:  Oncogene       Date:  2015-08-10       Impact factor: 9.867

3.  Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.

Authors:  Patrick J Grohar; Laure E Segars; Choh Yeung; Yves Pommier; Maurizio D'Incalci; Arnulfo Mendoza; Lee J Helman
Journal:  Clin Cancer Res       Date:  2013-11-25       Impact factor: 12.531

4.  SW-620 cells treated with topoisomerase I inhibitor SN-38: gene expression profiling.

Authors:  Vinicius Souza; Yan Bin Dong; H Sam Zhou; Wolfgang Zacharias; Kelly M McMasters
Journal:  J Transl Med       Date:  2005-12-23       Impact factor: 5.531

5.  Methyl pyruvate protects a normal lung fibroblast cell line from irinotecan-induced cell death: Potential use as adjunctive to chemotherapy.

Authors:  Bernice Monchusi; Monde Ntwasa
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

6.  A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo.

Authors:  Jianling Zou; Shuang Li; Zuhua Chen; Zhihao Lu; Jing Gao; Jianyin Zou; Xiaoting Lin; Yanyan Li; Cheng Zhang; Lin Shen
Journal:  Cell Death Dis       Date:  2018-05-31       Impact factor: 8.469

7.  Novel chemotherapeutic agent, FND-4b, activates AMPK and inhibits colorectal cancer cell proliferation.

Authors:  Heather F Sinner; Jeremy Johnson; Piotr G Rychahou; David S Watt; Yekaterina Y Zaytseva; Chunming Liu; B Mark Evers
Journal:  PLoS One       Date:  2019-10-24       Impact factor: 3.240

8.  Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.

Authors:  T Powles; J Shamash; D Berney; R T D Oliver
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

9.  Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.

Authors:  S M Harris; P Mistry; C Freathy; J L Brown; P A Charlton
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.